Sunitinib administered on 2/1 schedule in patients with metastatic renal cell carcinoma: the RAINBOW analysis.
暂无分享,去创建一个
C. Porta | G. Ceresoli | L. Boni | B. Escudier | G. Di Lorenzo | R. Iacovelli | M. Santoni | M. Sisani | S. Bracarda | F. Morelli | G. Procopio | F. Longo | R. Sabbatini | G. Cartenì | L. Derosa | C. Caserta | M. Rizzo | E. Verzoni | D. Gasparro | A. Altavilla | T. Sava | A. Mosca | R. Ricotta | M. Rossi | L. Galli | A. Camerini | A. Martignetti | A. Hamzaj | F. Massari | Matteo Santoni | G. D. Lorenzo | C. Boni | C. Porta | Luca Boni | Laura Galli | G. Procopio | Flavia Longo | Franco Morelli | Amelia Altavilla | Daniele Santini | Luigi Cavanna | D. Santini | L. Boni | L. Galli
[1] E. Jonasch,et al. Alternate sunitinib schedules in patients with metastatic renal cell carcinoma. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.
[2] A. Kiss,et al. Reprint of: Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: Correlation with dynamic microbubble ultrasound data and review of the literature. , 2014, Urologic oncology.
[3] Y. Najjar,et al. A 2 weeks on and 1 week off schedule of sunitinib is associated with decreased toxicity in metastatic renal cell carcinoma. , 2014, European journal of cancer.
[4] Kazuhiko Yoshida,et al. Superior tolerability of altered dosing schedule of sunitinib with 2-weeks-on and 1-week-off in patients with metastatic renal cell carcinoma--comparison to standard dosing schedule of 4-weeks-on and 2-weeks-off. , 2014, Japanese journal of clinical oncology.
[5] M. Sisani,et al. GOAL: an inverse toxicity-related algorithm for daily clinical practice decision making in advanced kidney cancer. , 2014, Critical reviews in oncology/hematology.
[6] T. Bathala,et al. Clinical outcomes for patients with metastatic renal cell carcinoma treated with alternative sunitinib schedules. , 2014, The Journal of urology.
[7] A. Ravaud,et al. Clinical biomarkers of response in advanced renal cell carcinoma. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.
[8] T. Choueiri. Clinical treatment decisions for advanced renal cell cancer. , 2013, Journal of the National Comprehensive Cancer Network : JNCCN.
[9] B. Neri,et al. Biweekly sunitinib regimen reduces toxicity and retains efficacy in metastatic renal cell carcinoma: A single‐center experience with 31 patients , 2013, International journal of urology : official journal of the Japanese Urological Association.
[10] G. Sonpavde,et al. Optimal Management of Metastatic Renal Cell Carcinoma: Current Status , 2013, Drugs.
[11] N. Sakuragi,et al. Randomized controlled trial versus comparative cohort study in verifying the therapeutic role of lymphadenectomy in endometrial cancer , 2013, International Journal of Clinical Oncology.
[12] J. Burke,et al. Randomized phase II trial of sunitinib on an intermittent versus continuous dosing schedule as first-line therapy for advanced renal cell carcinoma. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] A. Ravaud. Treatment-associated adverse event management in the advanced renal cell carcinoma patient treated with targeted therapies. , 2011, The oncologist.
[14] G. Demetri,et al. Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis , 2010, Cancer Chemotherapy and Pharmacology.
[15] Wanling Xie,et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[16] Xin Huang,et al. Overall Survival and Updated Results for Sunitinib Compared With Interferon Alfa in Patients With Metastatic Renal Cell Carcinoma , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] A. Ravaud,et al. How to optimise treatment compliance in metastatic renal cell carcinoma with targeted agents. , 2009, Annals of oncology : official journal of the European Society for Medical Oncology.
[18] S. Silverman,et al. From randomized controlled trials to observational studies. , 2009, The American journal of medicine.
[19] J. Irani. [Sunitinib versus interferon-alpha in metastatic renal-cell carcinoma]. , 2007, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie.
[20] R. Figlin,et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. , 2007, The New England journal of medicine.
[21] M. Blute. Sunitinib in patients with metastatic renal cell carcinoma , 2006 .
[22] A. Kiss,et al. Outcomes in patients with metastatic renal cell cancer treated with individualized sunitinib therapy: correlation with dynamic microbubble ultrasound data and review of the literature. , 2014, Urologic oncology.
[23] E. Jonasch,et al. Clinical Outcomes in Metastatic Renal Cell Carcinoma Patients Treated with Alternative Sunitinib Schedules , 2013 .
[24] E. Raymond,et al. Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.